Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapRI II in resected pancreatic adenocarcinoma
ISRCTN79802092Phase 2Terminated
- Sponsor
- Heidelberg University
- Start
- Oct 2008
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, interferon alfa-2b and cisplatin in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Heidelberg University. Primary endpoint: Event-free survival. Started Oct 2008; status: terminated.
02
Drugs
fluorouracilinterferon alfa-2bcisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN79802092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79802092.